JPRN-UMIN000002456已完成2 期
Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents. - Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.
Saitama Breast Cancer Clinical Study Group(SBCCSG)0 个研究点目标入组 30 人开始时间: 2009年9月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Concomitant infectious disease 2) History of lung disease, pulmonary fibrosis 3) Uncontrollable complication heart disease 4) have hypersensitivity to lapatinib and capecitabine 5) During pregnancy or lactation 6) History of serious hypersensitivity to fluoropyrimidines 7) Patients who received previous treatment with oral fluoropyrimidines within 12 months 8)The patient who has the risk of the extension at QT intervals is a case who assumes that it consults the specialist, and the treatment of the examination is inapposite. 9) Present case to whom radiation therapy is enforced 10) Doctors decision for excluion
研究者
相似试验
进行中（未招募）
1 期
A Phase II study of lapatanib and capecitabine in the treatment of metastatic pancreatic cancer - metastatic pancreatic cancer trialMetastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2008-006907-22-IEICORG - the All-Ireland Cooperative Oncology Research Group57
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyBrain metastases from ErbB2-positive breast cancerMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-IEGlaxoSmithKline Research & Development Ltd.110
进行中（未招募）
1 期
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyEstudio fase II de lapatinib y topotecán (Hycantin) o lapatinib y capecitabina (Xeloda) en el tratamiento de metástasis cerebrales recurrentes en pacientes con cáncer de mama ErbB2 positivo tras radioterapia cranealMetástasis cerebrales en pacientes con cáncer de mama ErbB2-positivoMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-ESGlaxoSmithKline S.A.
进行中（未招募）
不适用
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyBrain metastases from ErbB2-positive breast cancerMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-GRGlaxoSmithKline Research & Development Ltd.110